Tue, Oct 27, 2026 - Page 184
24768 indexed SquawkNews stories from this UTC day. Showing 21961-22080.
L
Tieto Oyj aktualisiert Finanzkalender
Tieto Oyj hat eine Aktualisierung seines Finanzkalenders veröffentlicht.
EQUITY | Oct 27, 2026, 06:07 AM UTC
M
Pharming Group Reports Q3 Basic EPS of $0.032
EQUITY | Oct 27, 2026, 06:07 AM UTC
M
Elopak Q3 net profit rises 38% year over year
Elopak’s net profit attributable to shareholders rose 38% year over year in Q3 2026.
EQUITY | Oct 27, 2026, 06:07 AM UTC
M
Company Reports Q3 2026 Profit From Property Management Per Share Up 37%
The company reported that profit from property management per share rose 37% in the third quarter of 2026.
EQUITY | Oct 27, 2026, 06:07 AM UTC
M
Novartis Reports Third-Quarter Sales of $14.5B
EARNINGS | Oct 27, 2026, 06:07 AM UTC
M
Elopak Q3 Net Profit Rises 38% to EUR 25 Million
Elopak reported Q3 net profit attributable to shareholders of EUR 25 million, up 38% year on year.
EQUITY | Oct 27, 2026, 06:07 AM UTC
L
Arcadis to support 3M on multi-year PFAS remediation program
Arcadis will support 3M in delivering a multi-year remediation program for PFAS contamination around 3M’s Zwijndrecht site.
EQUITY | Oct 27, 2026, 06:07 AM UTC
L
Tieto Updates Financial Calendar
Tieto published an update to its financial calendar. The body says the update concerns fourth-quarter and full-year 2026 results.
EQUITY | Oct 27, 2026, 06:07 AM UTC
M
Elopak Reports Higher Q3 Profit and Revenue
Elopak reported year-over-year increases in Q3 net profit attributable to shareholders and revenue.
EQUITY | Oct 27, 2026, 06:07 AM UTC
L
Tekova Reports Nine-Month Net Sales of EUR 77.9 Million
EARNINGS | Oct 27, 2026, 06:07 AM UTC
L
USPTO Issues Patent Notice of Allowance for Irlab Drug Candidate IRL1117
EQUITY | Oct 27, 2026, 06:07 AM UTC
M
Basilea Pharmaceutica Expects 2026 Revenue of Around CHF 310 Million
EARNINGS | Oct 27, 2026, 06:07 AM UTC
L
Tieto Updates Its Financial Calendar
Tieto says it will publish its fourth-quarter 2026 interim report.
EQUITY | Oct 27, 2026, 06:07 AM UTC
L
Idorsia Enrolls First Patients in QUVIVIQ Trial for US Label Update
Idorsia says it has enrolled the first patients in a QUVIVIQ trial seeking a US label update for daytime functioning benefits.
EQUITY | Oct 27, 2026, 06:07 AM UTC
L
Klaveness Combination Carriers ASA (KCC) Q3 EBITDA $40.4M; Dividend +20%
Klaveness Combination Carriers ASA posted Q3 2026 EBITDA of $40.4M and profit after tax of $23.6M, and raised its quarterly dividend 20% to $0.36 per share. KCC guides record Q4 with CABU TCE $43k—48k/day and CLEANBU $57
EARNINGS | Oct 27, 2026, 06:07 AM UTC
L
Innate Pharma Shifts PACIFIC-9 Trial Readout to H1 2027
AstraZeneca now expects high-level data from the Phase 3 PACIFIC-9 trial in H1 2027, revised from H2 2026. Enrollment is complete, and the study is event-driven.
EQUITY | Oct 27, 2026, 06:07 AM UTC
L
Tieto Updates Financial Calendar
Tieto says it will publish its fourth-quarter report.
EQUITY | Oct 27, 2026, 06:07 AM UTC
M
Offshore yuan hits 51-month high against dollar
The dollar fell from Tuesday’s 6.6704 high to a 51-month low of 6.6665 against the offshore yuan. A brief move above 6.6700 failed to trigger more short-covering.
FX | Oct 27, 2026, 06:07 AM UTC
L
Nomura Sees Limited Short-Term Returns From Li Ning Investments
Nomura analysts say Li Ning’s investments may support long-term prospects but offer limited short-term returns.
EQUITY | Oct 27, 2026, 06:07 AM UTC
L
Abionyx Pharma Partners With Axplora to Purify CER-001
Abionyx Pharma says it has partnered with Axplora on purification of CER-001.
EQUITY | Oct 27, 2026, 06:06 AM UTC
L
Abionyx Pharma partners with Axplora to produce CER-001
Abionyx Pharma has entered a production partnership with Axplora for CER-001.
EQUITY | Oct 27, 2026, 06:06 AM UTC
L
SIG Targets Adjusted EBIT Margin Above 18% in Medium Term
SIG targets an adjusted EBIT margin above 18% in the medium term.
EARNINGS | Oct 27, 2026, 06:06 AM UTC
L
Idorsia Enrolls First Patients in US Study of Quviviq Daytime Effects
Idorsia says the first patients have entered a US study examining daytime effects of Quviviq.
EQUITY | Oct 27, 2026, 06:06 AM UTC
M
HSBC Reports Third-Quarter Revenue and Pretax Profit
HSBC reported third-quarter revenue and pretax profit.
EQUITY | Oct 27, 2026, 06:06 AM UTC
L
Vend Marketplaces expects 2026 performance in line with medium-term targets
EARNINGS | Oct 27, 2026, 06:06 AM UTC
M
Vend Marketplaces Expects 2026 Costs to Fall About NOK 250 Million
The company expects full-year 2026 operating expenses excluding cost of goods sold to decline by approximately NOK 250 million compared with 2025.
EARNINGS | Oct 27, 2026, 06:06 AM UTC
L
US Patent Office Signals Patent for IRLAB Therapeutics’ IRL1117 Candidate
The US Patent Office has indicated that a patent for IRLAB Therapeutics’ drug candidate IRL1117 is forthcoming.
EQUITY | Oct 27, 2026, 06:06 AM UTC
M
USD/CNH Hits 51-Month Low at 6.6665
USD/CNH fell from Tuesday’s high of 6.6704 to a 51-month low of 6.6665. A brief break above 6.6700 failed to trigger further short covering.
FX | Oct 27, 2026, 06:06 AM UTC
L
BRIEF-Sig Group Ag Expects FY Adjusted Ebit Margin Of 16.0-16.5%
BRIEF-Sig Group Ag Expects FY Adjusted Ebit Margin Of 16.0-16.5% Oct 27 (Reuters) - SIG GROUP AG SIG
EARNINGS | Oct 27, 2026, 06:06 AM UTC
L
IRLAB får USA-patent för IRL1117
IRLAB Therapeutics har fått besked om ett amerikanskt patent för IRL1117.
EQUITY | Oct 27, 2026, 06:06 AM UTC
M
Pharming Group Reports 9M Gross Profit of $102.2 Million
EARNINGS | Oct 27, 2026, 06:06 AM UTC
L
IRLAB Receives U.S. Notice of Allowance for IRL1117 Patent
IRLAB Therapeutics received a U.S. notice of allowance for its IRL1117 patent.
EQUITY | Oct 27, 2026, 06:06 AM UTC
M
SIG Targets Medium-Term Adjusted EBIT Margin
SIG aims to achieve an adjusted EBIT margin over the medium term.
EARNINGS | Oct 27, 2026, 06:06 AM UTC
L
PPI’s management result per share rises 37% in Q3 2026
PPI reported a 37% increase in management result per share for the third quarter of 2026.
EARNINGS | Oct 27, 2026, 06:06 AM UTC
M
PPI Q3 Net Operating Income More Than Triples to SEK 761 Million
PPI reported third-quarter 2026 net operating income of SEK 761 million, more than triple the prior-year amount.
EARNINGS | Oct 27, 2026, 06:06 AM UTC
L
India’s margin funding book sees nearly Rs 3,000 crore net outflow
The broker-funded margin trading facility book recorded its largest single-day net outflow on Friday, according to data released by mtf.trading.
EQUITY | Oct 27, 2026, 06:06 AM UTC
M
PPI’s Net Operating Income More Than Triples in Q3 2026
PPI reported net operating income in Q3 2026 at more than triple the prior level.
EARNINGS | Oct 27, 2026, 06:06 AM UTC
L
Indian Shares Seen Lower as Oil Stays Near Six-Month High, Fed in Focus
Indian shares were expected to open lower on Tuesday as Brent crude stayed near $115 a barrel and investors awaited the Federal Reserve's policy decision later in the week. GIFT Nifty futures were at 22,669.
EQUITY | Oct 27, 2026, 06:06 AM UTC
L
Klaveness Combination Carriers Declares Q3 2026 Dividend of $0.36 Per Share
Klaveness Combination Carriers declared a Q3 2026 dividend of $0.36 per share, totaling $21.40 million.
EQUITY | Oct 27, 2026, 06:06 AM UTC
M
Tata Motors Secures 87.8% of Iveco Shares Through Tender Offer
Tata Motors crossed the 80% threshold needed to take control of the Italian commercial vehicle maker after securing 87.8% of Iveco shares through its tender offer.
MNA | Oct 27, 2026, 06:06 AM UTC
M
PPI Q3 Net Operating Income More Than Triples
PPI said third-quarter rental income also more than tripled.
EARNINGS | Oct 27, 2026, 06:06 AM UTC
M
INFICON Q3 Operating Profit More Than Doubles Year Over Year
INFICON reported higher third-quarter operating profit and revenue year over year.
EQUITY | Oct 27, 2026, 06:06 AM UTC
L
Nvidia to invest $3 billion in Meta equity offering
Nvidia to invest $3 billion in Meta equity offering
NEWS | Oct 27, 2026, 06:06 AM UTC
L
ETFSWX Lists Additional Securities on JSE
EQUITY | Oct 27, 2026, 06:06 AM UTC
M
Novartis 3Q Kesimpta Sales Rise 22% to $1.48B at Constant Currency
EARNINGS | Oct 27, 2026, 06:06 AM UTC
M
Novartis Q3 core EPS grows 8%
EARNINGS | Oct 27, 2026, 06:06 AM UTC
L
Roche obtiene marcado CE para inmunoanalizador cobas smart e
EQUITY | Oct 27, 2026, 06:06 AM UTC
L
Roche receives CE marking for cobas smart e immunoassay analyzer
Roche received CE marking for its cobas smart e immunoassay analyzer.
EQUITY | Oct 27, 2026, 06:06 AM UTC
L
Arcadis to Lead PFAS Remediation Program in Belgium
Arcadis will lead a large-scale PFAS remediation program in Belgium.
EQUITY | Oct 27, 2026, 06:06 AM UTC
M
Vend Marketplaces Q3 EBITDA Margin Rises to 43%
Q3 EBITDA margin increased around 3 percentage points to 43%.
EARNINGS | Oct 27, 2026, 06:06 AM UTC
L
Roche Receives CE Mark for cobas smart e Immunoanalyser
Roche received CE marking for its cobas smart e Immunoanalyser.
EQUITY | Oct 27, 2026, 06:06 AM UTC
L
Roche receives CE mark for cobas smart e immunoassay analyzer
Roche has obtained CE marking for its cobas smart e immunoassay analyzer.
EQUITY | Oct 27, 2026, 06:06 AM UTC
L
Bank Millennium files expanded consolidated quarterly report form
Bank Millennium’s filing form lists selected financial data, but the supplied text contains no figures.
EQUITY | Oct 27, 2026, 06:06 AM UTC
L
Pharming Names Leverne Marsh and Kenneth Lynard Interim Co-CEOs
Pharming appointed Leverne Marsh and Kenneth Lynard as interim co-CEOs following Fabrice Chouraqui’s resignation.
EQUITY | Oct 27, 2026, 06:06 AM UTC
M
Novartis Expects Q3 Core Operating Income to Be In Line to Grow Low Single Digits
EARNINGS | Oct 27, 2026, 06:05 AM UTC
L
Pharming Names Leverne Marsh and Kenneth Lynard Interim Co-CEOs
Fabrice Chouraqui has stepped down, and Pharming named Leverne Marsh and Kenneth Lynard interim co-CEOs.
EQUITY | Oct 27, 2026, 06:05 AM UTC
L
Pharming Names Marsh and Lynard Interim Co-CEOs
Pharming appointed Leverne Marsh and Kenneth Lynard as interim co-CEOs following Fabrice Chouraqui’s departure.
EQUITY | Oct 27, 2026, 06:05 AM UTC
M
Novartis 3Q Kisqali Sales Rise 37% to $1.82B
Novartis reported third-quarter Kisqali sales of $1.82 billion, up 37% at constant currency.
EQUITY | Oct 27, 2026, 06:05 AM UTC
L
Bank Millennium Q3 Net Fee and Commission Income Reaches 213.4 Million Zlotys
Bank Millennium reported Q3 net fee and commission income of 213.4 million zlotys, versus 212 million zlotys expected in a Reuters poll.
EARNINGS | Oct 27, 2026, 06:05 AM UTC
M
Novartis Core Operating Income Margin Rises to 41.6%, Up 2 Points
EARNINGS | Oct 27, 2026, 06:05 AM UTC
L
Abionyx Pharma Finalizes Manufacturing Process for Recombinant Human ApoA-I
Abionyx Pharma finalized an end-to-end manufacturing process for recombinant human ApoA-I with Axplora.
EQUITY | Oct 27, 2026, 06:05 AM UTC
L
Bank Millennium Reports Q3 Net Interest Income of 1.48 Billion Zlotys
Q3 net interest income was 1.48 billion zlotys, matching the 1.48 billion zlotys expected in a Reuters poll.
EARNINGS | Oct 27, 2026, 06:05 AM UTC
M
Novartis Raises 2026 Adjusted Operating Profit Forecast
Novartis raised its forecast for adjusted operating profit in 2026.
EARNINGS | Oct 27, 2026, 06:05 AM UTC
L
Idorsia Seeks US Label Update for Quviviq
EQUITY | Oct 27, 2026, 06:05 AM UTC
M
Bank Millennium Q3 net profit reaches 400.4 million zlotys
Net profit was 400.4 million zlotys, versus 377 million zlotys expected in a Reuters poll.
EQUITY | Oct 27, 2026, 06:05 AM UTC
L
Arcadis to Lead PFAS Remediation Program in Belgium
EQUITY | Oct 27, 2026, 06:05 AM UTC
M
Basilea Raises 2026 Operating Profit Guidance to CHF 115 Million
Basilea expects 2026 operating profit of CHF 115 million, up from its previous forecast of CHF 70 million. It also raised its financial target for “Agenda 2030” and provided updates on late-stage clinical programs.
EARNINGS | Oct 27, 2026, 06:05 AM UTC
M
Thor Medical Enters Three-Year Supply Agreement
Thor Medical and Medicines Discovery Catapult entered a three-year supply agreement.
EQUITY | Oct 27, 2026, 06:05 AM UTC
M
Novartis Reports Lower Q3 Net Profit and Higher Net Sales
Novartis reported a sharp decline in Q3 2026 net profit and an increase in net sales.
EQUITY | Oct 27, 2026, 06:05 AM UTC
M
Novartis Q3 2026 Net Profit Falls 70%
Novartis reported net profit for the third quarter of 2026, down 70%.
EQUITY | Oct 27, 2026, 06:05 AM UTC
M
Novartis Q3 Net Income Falls 70% to USD 1.2 Billion
EARNINGS | Oct 27, 2026, 06:05 AM UTC
L
Klaveness Reports Q3 EBITDA of USD 40.4 Million
EARNINGS | Oct 27, 2026, 06:05 AM UTC
M
Elopak Q3 revenue rises 6.5%; EBITDA €51.90 million
Elopak reported Q3 2026 group revenue up 6.5%, EBITDA of EUR 51.90 million and an EBITDA margin of 16.8%.
EQUITY | Oct 27, 2026, 06:05 AM UTC
M
Novartis Reports Q3 Sales Growth and Margin Expansion, Raises Guidance
Novartis said sales grew and core margin expanded in Q3, and raised its full-year core operating income guidance.
EARNINGS | Oct 27, 2026, 06:05 AM UTC
L
Anadolu Sigorta appoints Serkan Uğraş Kaygalak as CEO
EQUITY | Oct 27, 2026, 06:05 AM UTC
L
Anadolu Sigorta Appoints Serkan Ugras Kaygalak as CEO
EQUITY | Oct 27, 2026, 06:05 AM UTC
L
SED Energy Firm Contract Period Estimated at $87 Million
The firm contract period is estimated at $87 million, including mobilization fees.
EQUITY | Oct 27, 2026, 06:05 AM UTC
M
Vend Marketplaces Reports Q3 EBITDA of NOK 711 Million, Up 11%
EARNINGS | Oct 27, 2026, 06:05 AM UTC
L
Elopak Reports Q3 EBITDA of EUR 51.9 Million
EARNINGS | Oct 27, 2026, 06:05 AM UTC
L
KCC Provides Third-Quarter 2026 Dividend Information
KCC published key information relating to its dividend for the third quarter of 2026.
EQUITY | Oct 27, 2026, 06:05 AM UTC
M
SIG Group Reports Q3 Revenue of EUR 843 Million
SIG Group reported Q3 revenue of EUR 843 million. The report also cites a Q3 adjusted EBITDA margin of 25, with no unit specified.
EQUITY | Oct 27, 2026, 06:05 AM UTC
L
ABIONYX Pharma to Purify CER-001 at Axplora’s Pompey Site
Purification for CER-001 will be carried out at Axplora’s site in Pompey, France.
EQUITY | Oct 27, 2026, 06:05 AM UTC
L
Pharming Group Reports 9M Net Income of USD 18.9 Million
EARNINGS | Oct 27, 2026, 06:05 AM UTC
L
Thor Medical ASA Joins GBP 18.80 Million Consortium for UK PB-212 Supply Chain
A GBP 18.80 million consortium will establish a UK supply chain for PB-212.
EQUITY | Oct 27, 2026, 06:05 AM UTC
L
Basilea to Initiate Phase 2/3 Study in Mid-2027
Basilea Pharmaceutica plans to initiate a Phase 2/3 study for ceftibuten-ledaborbactam in mid-2027.
EQUITY | Oct 27, 2026, 06:05 AM UTC
L
SED Energy Receives Award for 30-Month Offshore Drilling Campaign in Malaysia
SED Energy received an award for a 30-month offshore drilling campaign in Malaysia.
EQUITY | Oct 27, 2026, 06:05 AM UTC
M
SATS ASA Q3 EBIT Before IFRS 16 Rises 33% to NOK 182 Million
Q3 EBIT before IFRS 16 was NOK 182 million, 33% above Q3 2025 and 35% higher on a currency-adjusted basis.
EARNINGS | Oct 27, 2026, 06:05 AM UTC
L
Qatar Airways Launches Codeshare Partnership With WestJet
Qatar Airways says it will add its QR code to WestJet flights across Canada.
EQUITY | Oct 27, 2026, 06:05 AM UTC
M
Cimsa Q3 Net Profit Rises to 1.8 Billion Lira
EQUITY | Oct 27, 2026, 06:04 AM UTC
L
Syncron Expands conet Partnership for Aftermarket Pricing and Planning Across EMEA
Syncron expanded its partnership with conet to support aftermarket pricing and planning delivery across EMEA.
EQUITY | Oct 27, 2026, 06:04 AM UTC
L
Vend Marketplaces Publishes Q3 2026 Interim Report
Vend Marketplaces ASA issued its interim report for the third quarter of 2026.
EQUITY | Oct 27, 2026, 06:04 AM UTC
L
Idorsia Expects DARI-DREAM Study Results in 2028
EQUITY | Oct 27, 2026, 06:04 AM UTC
L
Idorsia DARI-DREAM Phase 3 Study to Randomize 344 Participants
The DARI-DREAM Phase 3 study will randomize 344 participants to QUVIVIQ 50 mg or placebo.
EQUITY | Oct 27, 2026, 06:04 AM UTC
L
Novartis Had Seen 2026 Core Operating Profit Falling by Low Single-Digit
EARNINGS | Oct 27, 2026, 06:04 AM UTC
L
Pharming Group Reports 9M Net Income of USD 18.9 Million
EARNINGS | Oct 27, 2026, 06:04 AM UTC
M
Vend Marketplaces Reports Q3 Revenue of NOK 1,641 Million, Up 3% YoY
Q3 revenue rose 3% year over year and 6% in constant currency.
EQUITY | Oct 27, 2026, 06:04 AM UTC
L
PPI Reports Q3 Rental Income of SEK 887 Million
EQUITY | Oct 27, 2026, 06:04 AM UTC
M
SATS ASA Q3 Adjusted EBITDA Rises 25% to NOK 235 Million
EARNINGS | Oct 27, 2026, 06:04 AM UTC
M
INFICON Reports Record Third Quarter 2026, Raises Full-Year Guidance
INFICON reported a record third quarter in 2026 and raised its full-year guidance.
EARNINGS | Oct 27, 2026, 06:04 AM UTC
L
Tekova reports strong performance in business review
Tekova Oyj’s business review says strong performance continued.
EQUITY | Oct 27, 2026, 06:04 AM UTC
H
SIG GROUP AG - FULL-YEAR GUIDANCE ADJUSTED: EXPECTED ADJUSTED EBIT MARGIN INCREASED TO 16.0-16.5% (PREVIOUSLY 15.7-16.2%); SALES GROWTH AT C
SIG GROUP AG - FULL-YEAR GUIDANCE ADJUSTED: EXPECTED ADJUSTED EBIT MARGIN INCREASED TO 16.0-16.5% (P
EARNINGS | Oct 27, 2026, 06:04 AM UTC
M
Pharming Group generated US$32.4 million in Q3 operating cash flow
EQUITY | Oct 27, 2026, 06:04 AM UTC
M
SATS Q3 Revenue Rises 7% to NOK 1,324 Mln
EQUITY | Oct 27, 2026, 06:04 AM UTC
L
Russian defense ministry: Russian forces strike cargo ship in Black Sea
Russian defense ministry: Russian forces strike cargo ship in Black Sea
NEWS | Oct 27, 2026, 06:04 AM UTC
M
SATS ASA Q3 revenue rises 7% to NOK 1,324 million
SATS ASA reported Q3 2026 revenue of NOK 1,324 million, up 7% on an adjusted basis.
EQUITY | Oct 27, 2026, 06:04 AM UTC
L
Abionyx Pharma Pursues Regulatory Steps for LCAT Deficiency and Phase 2b Sepsis Trial
Abionyx Pharma is pursuing regulatory steps for LCAT deficiency and a Phase 2b sepsis trial.
EQUITY | Oct 27, 2026, 06:04 AM UTC
M
Novartis Expects Q3 Core Operating Income in Line to Low-Single-Digit Growth
Novartis revised its expectation for Q3 core operating income from a low-single-digit decline to in-line performance or low-single-digit growth.
EARNINGS | Oct 27, 2026, 06:04 AM UTC
L
Thor Medical and Medicines Discovery Catapult Enter Three-Year Supply Agreement
Thor Medical and Medicines Discovery Catapult entered a three-year supply agreement to support radiopharmaceutical development in the UK.
EQUITY | Oct 27, 2026, 06:04 AM UTC
L
Reinet Investments Updates Share Buyback Programme
Reinet Investments issued an update on its share buyback programme on 27 October 2026.
EQUITY | Oct 27, 2026, 06:04 AM UTC
L
Greencoat Renewables Buys Back Shares Worth EUR 109,882.538
Greencoat Renewables bought back 139 shares worth EUR 109,882.538.
EQUITY | Oct 27, 2026, 06:04 AM UTC
M
Basilea Raises FY26 Income Guidance to CHF 250M, Lifts 2030 Cash Target
Basilea raised FY26 guidance for Cresemba- and Zevtera-related income to CHF 250M, 19% above its prior guidance, and increased its cumulative cash flow target through 2030 to CHF 650M. The company also outlined streamlin
EARNINGS | Oct 27, 2026, 06:04 AM UTC
L
나스닥선물 -0.17%, S&P500 선물 +0.04%
나스닥선물 -0.17%, S&P500 선물 +0.04% 10월27일 (로이터) - 나스닥선물 -0.17%, S&P500 선물 +0.04% (15:00 현재) (신안나 기자) ((a
EQUITY | Oct 27, 2026, 06:04 AM UTC
H
KLAVENESS COMBINATION CARRIERS - Q4 2026 TCE EARNINGS GUIDANCE FOR CABU FLEET IS $43,000 - 48,000 $/DAY AND 57,000 - 67,000 $/DAY FOR CLEANB
KLAVENESS COMBINATION CARRIERS - Q4 2026 TCE EARNINGS GUIDANCE FOR CABU FLEET IS $43,000 - 48,000 $/
EARNINGS | Oct 27, 2026, 06:04 AM UTC
L
Idorsia Enrolls First Patients in US QUVIVIQ Phase 3 Study
The Dari-Dream study targets daytime functioning claims for QUVIVIQ 50 mg, with results expected during 2028.
EQUITY | Oct 27, 2026, 06:04 AM UTC
L
Roche Receives CE Mark for cobas Smart e Immunoanalyser
The compact platform has a planned menu of more than 100 assays and extends Roche’s cobas portfolio to smaller labs and clinics.
EQUITY | Oct 27, 2026, 06:04 AM UTC
H
Sig Group AG Raises Full-Year Adjusted EBIT Margin Guidance To 16.0-16.5%
SIG Group AG BX:1YQA
EARNINGS | Oct 27, 2026, 06:04 AM UTC
L
Bank Millennium Publishes Quarterly Report Form
Bank Millennium provided a form for its extended consolidated quarterly report, including selected financial data in thousands of PLN.
EQUITY | Oct 27, 2026, 06:03 AM UTC
M
百十四銀行 raises standalone ordinary profit forecast
The bank raised its standalone ordinary profit forecast by 18.6% from its previous forecast.
EARNINGS | Oct 27, 2026, 06:03 AM UTC
L
Sig Group Ag Expects FY Adjusted Ebit Margin Of 16.0-16.5%
SIG GROUP AG BX:1YQA
EARNINGS | Oct 27, 2026, 06:03 AM UTC
L
アマノ:27年3月期単体、予想経常利益145.00億円(従来比20.8%減) 、下方修正 (従来183.00億円)
アマノ:27年3月期単体、予想経常利益145.00億円(従来比20.8%減) 、下方修正 (従来183.00億円)
EQUITY | Oct 27, 2026, 06:03 AM UTC